Nanomaterial-mediated autophagy: coexisting hazard and health benefits in biomedicine DOI Creative Commons
Xiaoli Feng, Yaqing Zhang, Chao Zhang

и другие.

Particle and Fibre Toxicology, Год журнала: 2020, Номер 17(1)

Опубликована: Окт. 16, 2020

Widespread biomedical applications of nanomaterials (NMs) bring about increased human exposure risk due to their unique physicochemical properties. Autophagy, which is great importance for regulating the physiological or pathological activities body, has been reported play a key role in NM-driven biological effects both vivo and vitro. The coexisting hazard health benefits NM-mediated autophagy biomedicine are nonnegligible require our particular concerns.We collected research on toxic related Generally, NMs can be delivered into animal models through different administration routes, internalized by cells uptake pathways, exerting varying degrees damage tissues, organs, cells, organelles, eventually being deposited excreted from body. In addition, other NMs, such as oxidative stress, inflammation, necroptosis, pyroptosis, ferroptosis, have associated with cooperate regulate body activities. We therefore highlight that serves double-edged sword, could utilized treatment certain diseases dysfunction, cancer, neurodegenerative disease, cardiovascular disease. Challenges suggestions further investigations proposed purpose improve biosafety evaluation facilitate wide application. Databases PubMed Web Science were search relevant literature, included all published, Epub ahead print, in-process, non-indexed citations.In this review, we focus dual effect field. It become trend use treat clinical cancer diseases. Understanding regulatory mechanism also helpful reducing much possible.

Язык: Английский

microRNA Therapeutics in Cancer — An Emerging Concept DOI Creative Commons
Maitri Shah, Alessandra Ferrajoli, Anil K. Sood

и другие.

EBioMedicine, Год журнала: 2016, Номер 12, С. 34 - 42

Опубликована: Сен. 20, 2016

MicroRNAs (miRNAs) are an evolutionarily conserved class of small, regulatory non-coding RNAs that negatively regulate protein coding gene and other transcripts expression. miRNAs have been established as master regulators cellular processes, they play a vital role in tumor initiation, progression metastasis. Further, widespread deregulation microRNAs reported several cancers, with playing oncogenic suppressive roles. Based on these, emerged promising therapeutic tools for cancer management. In this review, we focused the roles tumorigenesis, miRNA-based strategies currently being evaluated use cancer, advantages current challenges to their clinic.

Язык: Английский

Процитировано

417

Autophagy as a molecular target for cancer treatment DOI
Nur Mehpare Kocatürk, Yunus Akkoç, Cenk Kığ

и другие.

European Journal of Pharmaceutical Sciences, Год журнала: 2019, Номер 134, С. 116 - 137

Опубликована: Апрель 11, 2019

Язык: Английский

Процитировано

343

Epidrugs: targeting epigenetic marks in cancer treatment DOI Open Access
Cristiana Libardi Miranda Furtado, Maria Cláudia dos Santos Luciano, Renan da Silva Santos

и другие.

Epigenetics, Год журнала: 2019, Номер 14(12), С. 1164 - 1176

Опубликована: Июль 6, 2019

Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly related to the genesis cancer. Unlike genetic mutations, ability reprogram landscape in cancer epigenome one most promising target therapies both treatment and reversibility drug resistance. Epigenetic alterations development progression may be basis for individual variation response. Thus, this review focuses on emerging area pharmaco(epi)genomics, specifically highlighting reprogramming during tumorigenesis how markers are targeted as a therapy (epidrugs) clinical implications treatment.

Язык: Английский

Процитировано

286

Treating cancer with microRNA replacement therapy: A literature review DOI Open Access
Nayer Hosseinahli, Mahyar Aghapour, Pascal H. G. Duijf

и другие.

Journal of Cellular Physiology, Год журнала: 2018, Номер 233(8), С. 5574 - 5588

Опубликована: Март 9, 2018

microRNAs (miRNAs) are small non‐coding RNAs that regulate gene expression post‐transcriptionally by interfering with the translation of one or more target mRNAs. The unique miRNA sequences involved in many physiological and pathological processes. Dysregulation miRNAs contributes to pathogenesis all types cancer. Notably, diminished tumor suppressor miRNAs, such as members Let‐7 miR‐34 family, promotes progression, invasion metastasis. past lustrum particular, has witnessed substantial improvement replacement therapy. This approach aims restore function cells using synthetic mimics plasmids. Here, we provide a comprehensive review recent advances therapy for treatment cancer its advantages over conventional We discuss wide variety delivery methods vectors, well obstacles remain be overcome. Lastly, efforts reverse epigenetic alterations, which affect cells, promising observation restoring re‐sensitizes resistant chemotherapeutic drugs. fact various therapies currently clinical trial demonstrates great potential this treat

Язык: Английский

Процитировано

278

miRNA nanotherapeutics for cancer DOI Creative Commons
Aditya Ganju, Sheema Khan, Bilal Bin Hafeez

и другие.

Drug Discovery Today, Год журнала: 2016, Номер 22(2), С. 424 - 432

Опубликована: Ноя. 2, 2016

Язык: Английский

Процитировано

276

RNAi-based therapeutics and tumor targeted delivery in cancer DOI
Göknur Kara, George A. Călin, Bülent Özpolat

и другие.

Advanced Drug Delivery Reviews, Год журнала: 2022, Номер 182, С. 114113 - 114113

Опубликована: Янв. 19, 2022

Язык: Английский

Процитировано

267

Non-coding RNAs and potential therapeutic targeting in cancer DOI
Shusuke Toden,

Timothy J. Zumwalt,

Ajay Goel

и другие.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2020, Номер 1875(1), С. 188491 - 188491

Опубликована: Дек. 13, 2020

Язык: Английский

Процитировано

230

A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies DOI Open Access
Alexis V. Forterre, Hiroaki Komuro, Shakhlo Aminova

и другие.

Cancers, Год журнала: 2020, Номер 12(7), С. 1852 - 1852

Опубликована: Июль 9, 2020

In the field of molecular oncology, microRNAs (miRNAs) and their role in regulating physiological processes cancer pathogenesis have been a revolutionary discovery over last decade. It is now considered that miRNA dysregulation influences critical pathways involved tumor progression, invasion, angiogenesis metastasis wide range types. Hence, altering levels cells has promising potential as therapeutic intervention, which discussed many other articles this Special Issue. Some most significant hurdles usage are stability delivery system. review, we cover comprehensive update on challenges strategies for development systems includes virus-based delivery, non-viral (artificial lipid-based vesicles, polymer-based or chemical structures), recently emerged extracellular vesicle (EV)-based systems.

Язык: Английский

Процитировано

194

Polymeric vehicles for nucleic acid delivery DOI
Alexandra S. Piotrowski-Daspit,

Amy C. Kauffman,

Laura G. Bracaglia

и другие.

Advanced Drug Delivery Reviews, Год журнала: 2020, Номер 156, С. 119 - 132

Опубликована: Янв. 1, 2020

Язык: Английский

Процитировано

157

MicroRNA Therapeutics in Cancer: Current Advances and Challenges DOI Open Access
Soha Reda El Sayed, Justine Cristante, Laurent Guyon

и другие.

Cancers, Год журнала: 2021, Номер 13(11), С. 2680 - 2680

Опубликована: Май 29, 2021

The discovery of microRNAs (miRNAs) in 1993 has challenged the dogma gene expression regulation. MiRNAs affect most cellular processes from metabolism, through cell proliferation and differentiation, to death. In cancer, deregulated miRNA leads tumor development progression by promoting acquisition cancer hallmark traits. multi-target action miRNAs, which enable regulation entire signaling networks, makes them attractive tools for anti-cancer therapies. Hence, supplementing downregulated synthetic oligonucleotides or silencing overexpressed miRNAs artificial antagonists became a common strategy research. However, ultimate success therapeutics will depend on solving pharmacokinetic targeted delivery issues. number nanocarrier-based platforms holds significant promises enhance specific controlled safety profile miRNA-based this review, we provide among comprehensive assessments date promising nanomedicine that have been tested preclinically, pertaining treatment selected solid tumors including lung, liver, breast, glioblastoma as well endocrine malignancies. future challenges potential applications clinical oncology are discussed.

Язык: Английский

Процитировано

136